MicroRNAs in the pathogenesis of neurodegenerative disorders: Potential as therapeutic targets.
MicroRNAs in the pathogenesis of neurodegenerative disorders: Potential as therapeutic targets.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Dayton, US · Author affiliation
Department of Biology, University of Dayton, Dayton, OH, USA.Location evidence
Terre Haute, US · Author affiliation
Center for Genomic Advocacy (TCGA), Indiana State University, Terre Haute, IN, USA.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Neurodegenerative diseases (neurodegenerative disorders) are marked by the progressive degeneration of the structure and function of the central nervous system. They may result in the deterioration of cognitive, motor, and functional abilities. Diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis represent some of the most prominent examples of neurodegenerative disorders. Despite scientific advancement in understanding disease pathology and prognosis, the therapeutic strategies available for management remain limited. In recent years, microRNAs, small non-coding RNA molecules, have emerged as key players in the pathogenesis of neurodegenerative disorders. Therefore, understanding how these microRNAs affect disease pathology and pathway signaling is essential, and may open microRNAs as new avenues for potential therapeutic intervention. This review explores the role of microRNAs in various neurodegenerative diseases, discuss how microRNAs affect signaling pathways, and examine the potential of microRNAs as therapeutic targets.